Novartis’ big push into cell and gene therapy hasn’t been the smoothest of rides, with a data manipulation scandal hamstringing Zolgensma and manufacturing concerns hurting CAR-T cancer therapy Kymriah. Could a new European facility help turn around the latter’s production bottleneck? Novartis last week opened its newest cell and gene therapy facility in Stein, Switzerland,… Read More »
FDA Approves Reblozyl (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions Print this page SUMMIT, N.J. & CAMBRIDGE, Mass.–(BUSINESS WIRE)– Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced the U.S. Food and Drug Administration (FDA) has approved Reblozyl (luspatercept-aamt) for the… Read More »
Turkey provides cutting-edge medical services, including stem cell transplants, to millions – including the refugees it hosts – said a Turkish professor of hematology. Fevzi Altuntaş told Anadolu Agency (AA) that Turkey emulated developed countries in the West in its drive to offer patients high-end medical services. Altuntaş, founder of Turkish cord blood and bone… Read More »
Print this page KENILWORTH, N.J.–(BUSINESS WIRE) December 19, 2018 –Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC), based… Read More »